IFRX
InflaRx N.V.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$120.73M
P/E Ratio
—
EPS
$-0.80
Beta
1.51
52W High
$1.98
52W Low
$0.71
50-Day MA
$1.05
200-Day MA
$1.11
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About InflaRx N.V.
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Fundamentals
| Revenue (TTM) | 29,330 |
| Gross Profit (TTM) | $-7.24M |
| EBITDA | $-48.20M |
| Operating Margin | 37898.00% |
| Return on Equity | -88.60% |
| Return on Assets | -46.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.68 |
| Price-to-Book | 2.48 |
| Price-to-Sales (TTM) | 4116.09 |
| EV/Revenue | 1957.93 |
| EV/EBITDA | 0.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -80.80% |
| Shares Outstanding | $72.29M |
| Float | $60.02M |
| % Insiders | 5.98% |
| % Institutions | 27.21% |
Historical Volatility
HV 10-Day
171.88%
HV 20-Day
126.16%
HV 30-Day
117.78%
HV 60-Day
94.25%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($8.58 target)
1
Strong Buy5
Buy2
HoldData last updated: 4/30/2026